


AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS


Claims 1-18 (cancelled).

19. (new) A compound of the formula (I)



or a pharmaceutically acceptable salt of the compound, prodrug of the compound or ester of the compound, wherein:

G is selected from the group consisting of



where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C₁-C₆ alkyl, phenyl and phenyl-C₁-C₄-alkyl, and R' is selected from the group consisting of H and C₁-C₄ alkyl;

B is (CH₂)_m(CH=CH)_pY, wherein m = 1,2,3, p = 0 and Y is CH₂;

X is selected from the group consisting of CH₂ and C=O;

R₁ is selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃;


A is selected from the group consisting of CH₂, NH, O, and S(O)_n wherein n is zero, 1 or 2;

R₂ is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole, unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃; and

R is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₄ alkynyl, aryl and aryl-C₁-C₄ alkyl.


20. (new) A compound according to claim 19, wherein

G is selected from the group consisting of




R₂ is selected from the group consisting of phenyl, thiophene, oxazole, isoxazole, and pyridine, unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen and CF₃.

21. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt of the compound, prodrug of the compound or ester of the compound having the formula (I):



wherein:

G is selected from the group consisting of



where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C₁-C₆ alkyl, phenyl, and phenyl-C₁-C₄-alkyl, and R' is selected from the group consisting of H and C₁-C₄ alkyl;

B is (CH₂)_m(CH=CH)_pY, wherein m = 1,2,3, p = 0 and Y is CH₂;

X is selected from the group consisting of CH₂ and C=O;

R₁ is selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃;


A is selected from the group consisting of CH₂, NH, O, and S(O)_n wherein n is zero, 1 or 2;

R₂ is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole, unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃; and

R is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₄ alkynyl, aryl and aryl-C₁-C₄ alkyl.


22. (new) A pharmaceutical composition of claim 21 wherein:

G is selected from the group consisting of










R2 is selected from the group consisting of phenyl, thiophene, oxazole, isoxazole, and pyridine, unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen and CF₃.

23. (new) A method for treating a condition mediated by the $\alpha_v\beta_3$ integrin in a mammal in need of such treatment, including a human, comprising administering to said mammal an effective $\alpha_v\beta_3$ inhibiting amount of a compound of formula (I)



or a pharmaceutically acceptable salt of the compound, prodrug of the compound or ester of the compound, wherein:

G is selected from the group consisting of



;

where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C₁-C₆ alkyl, phenyl, and phenyl-C₁-C₄-alkyl, and R' is

selected from the group consisting of H and C₁-C₄ alkyl;

B is (CH₂)_m(CH=CH)_pY, wherein m = 1,2,3, p = 0 and Y is CH₂;

X is selected from the group consisting of CH₂ and C=O;

R1 is selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃;


A is selected from the group consisting of CH₂, NH, O, and S(O)_n wherein n is zero, 1 or 2;

R2 is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃; and

R is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₄ alkynyl, aryl and aryl-C₁-C₄ alkyl.

24. (new) The method of claim 23 wherein:

G is selected from the group consisting of




R2 is selected from the group consisting of phenyl, thiophene, oxazole, isoxazole, and pyridine unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen and CF₃.

25. (new) The method according to claim 23, wherein the condition treated is selected from the group consisting of bone resorption, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, neoplasia, angiogenesis, diabetic retinopathy, arthritis, psoriasis, periodontal disease and smooth muscle cell migration.


26. (new) The method according to claim 23, wherein the condition treated is selected from the group consisting of solid tumor growth, tumor angiogenesis and restenosis.

27. (new) A combined method of treatment of cancer or of controlling the growth of a neoplasm in a mammal suffering from cancer, including a human, the method comprising administering simultaneous, separately or sequentially, a compound of formula (I)



or a pharmaceutically acceptable salt of the compound, a prodrug of the compound or an ester of the compound, wherein:

G is selected from the group consisting of



where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C₁-C₆ alkyl, phenyl, and phenyl-C₁-C₄-alkyl, and R' is selected from the group consisting of H and C₁-C₄ alkyl;

B is (CH₂)_m(CH=CH)_pY, wherein m = 1,2,3, p = 0 and Y is CH₂;

X is selected from the group consisting of CH₂ and C=O;

R1 is selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH,

halogen, and CF₃;

A is selected from the group consisting of CH₂, NH, O, and S(O)_n wherein n is zero, 1 or 2;


R₂ is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃; and

R is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₄ alkynyl, aryl and aryl-C₁-C₄-alkyl; and

an additional antitumor agent; in amounts and close enough together in time sufficient to produce a therapeutically useful effect.


28. (new) The method according to claim 27, wherein the additional antitumor agent is selected from the group consisting of an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.

29. (new) A product containing a compound of formula (I) a compound of formula (I)



or a pharmaceutically acceptable salt of the compound, a prodrug of the compound or an ester of the compound, wherein:

G is selected from the group consisting of



where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C₁-C₆ alkyl, phenyl, and phenyl-C₁-C₄-alkyl, and R' is selected from the group consisting of H and C₁-C₄ alkyl;

B is (CH₂)_m(CH=CH)_pY, wherein m = 1,2,3, p = 0 and Y is CH₂;

X is selected from the group consisting of CH₂ and C=O;

R₁ is selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃;

A is selected from the group consisting of CH₂, NH, O, and S(O)_n wherein n is zero, 1 or 2;

R₂ is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃; and

R is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₄ alkynyl, aryl and aryl-C₁-C₄ alkyl; and

an effective antineoplastic amount of an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

30. (new) The product according to claim 29, wherein the additional antitumor agent is selected from an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an

antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.

31. (new) A combined method of treatment of cancer or of controlling the growth of a neoplasm in a mammal suffering from cancer, including a human, said method comprising administering simultaneous, separately or sequentially, a compound selected from the group consisting of:

3-phenyl-N-{4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-phenyl-N-{4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-phenyl-N-{4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

3-(3-pyridinyl)-N-{4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-(3-pyridinyl)-N-{4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-(3-pyridinyl)-N-{4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-

yl)-3-phenyl-beta-alanine,

N-{3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-phenyl-beta-alanine,

N-{3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-phenyl-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-phenyl-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-phenyl-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-phenyl-beta-alanine,

N-{3-oxo-4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-(3-pyridinyl)-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-(3-pyridinyl)-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-(3-pyridinyl)-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-3-(3-pyridinyl)-beta-alanine,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,

3-({3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,

3-({3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

4-{3-oxo-4-[4-(pyridin-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[3-(1H-imidazol-2-ylamino)-propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[4-(1H-imidazol-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[4-(pyridin-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid,

4-{3-oxo-4-[3-(1H-imidazol-2-ylamino)-propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid, and

4-{3-oxo-4-[4-(1H-imidazol-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-

benzoxazin-7-yl)-3-(3-pyridinyl)butanoic acid or a pharmaceutically acceptable salt of said compound; and

an additional antitumor agent; in amounts and close enough together in time sufficient to produce a therapeutically useful effect.

32 (new) The method according to claim 31 wherein the additional antitumor agent is selected from the group consisting of an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.

33. (new) A product containing a compound selected from the group consisting of:

3-phenyl-N-{4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-phenyl-N-{4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-phenyl-N-{4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

3-(3-pyridinyl)-N-{4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-(3-pyridinyl)-N-{4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-(3-pyridinyl)-N-{4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{3-oxo-4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-

benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,
3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,
3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,
3-({3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,
3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,
3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,
3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(pyridinyl)propanoic acid,
3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,
3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,
3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,
3-({3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,
3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,
3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,
3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,
4-{3-oxo-4-[4-(pyridin-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,
4-{3-oxo-4-[3-(1H-imidazol-2-ylamino)-propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[4-(1H-imidazol-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[4-(pyridin-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid,

4-{3-oxo-4-[3-(1H-imidazol-2-ylamino)-propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid, and
4-{3-oxo-4-[4-(1H-imidazol-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid or a pharmaceutically acceptable salt of said compound; and

an effective antineoplastic amount of an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

34. (new) The product according to claim 33, wherein the additional antitumor agent is selected from an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.